Anti- screening of MMV pandemic response box and evaluation of RWJ-67657 efficacy in chronically infected mice.

Toxoplasmosis is a significant public health concern with limited therapeutic options. The medicines for malaria venture (MMV) developed the pandemic response box (PRB) containing 400 drug-like molecules with broad pathogen activity. The aim of this work is to evaluate PRB compounds for their anti- activity and identify promising candidates for further evaluation.

Repurposing the Medicines for Malaria Venture's COVID Box to discover potent inhibitors of Toxoplasma gondii, and in vivo efficacy evaluation of almitrine bismesylate (MMV1804175) in chronically infected mice.

Toxoplasmosis, caused by the obligate intracellular parasite Toxoplasma gondii, affects about one-third of the world's population and can cause severe congenital, neurological and ocular issues. Current treatment options are limited, and there are no human vaccines available to prevent transmission. Drug repurposing has been effective in identifying anti-T.

Seroprevalence and risk factors associated with infection in pregnant individuals from a Brazilian Amazon municipality.

The aim of this study was to determine the prevalence and to identify the risk factors associated with infection in pregnant individuals living in the Ponta de Pedras municipality, Marajó Archipelago, State of Pará, where an outbreak of toxoplasmosis occurred in 2013. From 2014 to March 2017, a cross-sectional study was conducted, including 555 pregnant individuals aged 13- to 42-years-old. Serological tests (enzyme immunoassays) were performed, and socioenvironmental and behavioral information were obtained through the application of a questionnaire.